The death of a study volunteer further complicates the path forward for Intellia’s on-hold rare disease treatment. Elsewhere, Gilead reported a setback and J&J netted a first-of-its-kind approval.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Recursion announced Najat Khan, PhD, currently chief R&D and commercial officer and a board member, will succeed co-founder and CEO Chris Gibson, PhD as CEO and president. Khan will also continue in ...

Q3 2025 Management View Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

Use these Linux commands to quickly search and find anything from the Linux terminal, without digging through folders in a GUI file manager.

Bristol Myers Squibb is shedding two clinical programs, one from its 2023 Mirati buyout and another from a partnership with U ...

Threat actors refine tactics with DNS attacks, new RATs, and Rust-based malware. Stay ahead with this week’s top ThreatsDay ...

WEST LAFAYETTE, Ind. — It took some time, but the changes Rutgers made leading up to its biggest game of the year were enough to salvage its season. After being carved up and shut down early, the ...

Abstract: The dynamic model equations are essential in system analysis and control system design. In adaptive control systems, the mathematical equations of the controlled system are utilized to ...

Finally, add Recursion Pharmaceuticals (NASDAQ: RXRX) to your list of growth stocks to invest in right now if you've got $1,000 you're ready to put to work and don't mind taking a little risk.